Xenetic Biosciences’ contracts and arrangements with Baxter Healthcare SA and Baxter Healthcare Corp., have now been assigned to Baxalta Inc. as part of the spin out of the company’s biopharmaceutical business.    Xenetic has an exclusive research, development, license and supply agreement with Baxalta to develop products with an extended half-life of certain proteins and molecules using its PolyXen technology. The resulting drug candidate is designed to create a longer-acting haemophilia drug...